11 Early-Phase Trials to Watch Now

Early-phase trials were once treated as scientific checkpoints, important but operationally distant. That is no longer the case. Today, Phase 1 and early Phase 2 studies are where many of the assumptions that influence later clinical trial design first take form. Eligibility frameworks begin to take shape, biomarker strategies emerge, and protocol documentation expands. Most importantly, the drivers of future amendment risk become visible long before pivotal studies begin.

For clinical development and operations leaders, these trials provide early signals that influence feasibility, startup planning, and long-term execution strategy:

Will this mechanism require biomarker-defined enrollment?
Will visit intensity or specialty procedures limit site scalability?
Are protocol assumptions likely to evolve, which may contribute to downstream amendments as development progresses?

Recognizing these signals early allows teams to address design vulnerabilities before they scale into costly protocol amendments or operational delays.

In this article, we aim to facilitate decision intelligence rather than a simple recap. Read on to see which early-phase trials are signaling the biggest shifts in clinical trial design.

11 Early-Phase Trials Across Key Therapeutic Areas

Signaling Shifts in Clinical Trial Design

Breast Cancer

•OP-3136 (KAT6 Inhibitor)
•NGC-Cap (PCS6422 + Capecitabine)
•(Z)-Endoxifen (Oral ER modulator)
•α-Lactalbumin Preventive Vaccine

Neurology

•NMRA-511 – Alzheimer's Disease
•ML-007C-MA – Alzheimer's Disease Psychosis
•DNL628 / DNL921 – Alzheimer's Disease
•Buntanetap (ANVS401) – Parkinson's Disease
•GT-02287 – Parkinson's Disease

Other Oncology

•ART-101 – Prostate Cancer
•REC-4881 – Colon Cancer / Hereditary Polyposis

1. OP-3136 (KAT6 Inhibitor) – Breast Cancer

What It Is:

OP-3136 is a first-in-human Phase 1 oncology study evaluating an oral inhibitor of lysine acetyltransferases KAT6A and KAT6B, a class of epigenetic regulators implicated in cancer biology. The study is designed to assess safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and exploratory biomarkers to inform dose selection, potential cohort expansion, and downstream development planning.

Why It Matters:

Targeting epigenetic mechanisms such as KAT6A/B introduces uncertainty into early clinical trial design because the relationship between dose, target engagement, and clinical effect is still being defined. Early exploratory biomarker findings may prompt protocol amendments or adaptive design decisions once safety and signal data emerge, particularly in indications like hormone-dependent breast cancer.

Real-World Site Impact:

Sites face shifting eligibility logic during early enrollment, driving repeated screening reinterpretation and added coordinator workload. Screening increasingly depends on pathology and molecular reports rather than structured EHR fields, extending screening timelines and increasing sponsor clarification cycles.

💡

Pro Tip:

Sites benefit from eligibility workflows that evolve without operational resets. Some teams use agentic AI platforms like Kitsa to track why criteria change, apply updates consistently, and preserve clinical trial documentation continuity as early assumptions mature.

2. NGC-Cap (PCS6422 + Capecitabine) – Breast Cancer

What It Is:

NGC-Cap is a randomized Phase 2 study comparing a combination regimen against capecitabine alone in advanced or metastatic breast cancer. Interim analyses assess safety, dose optimization, and early efficacy to guide continuation decisions and refine treatment arms.

Why It Matters:

Combination regimens materially increase clinical trial design complexity. Safety monitoring becomes layered, adverse-event attribution more nuanced, and dose-adjustment rules more restrictive, often exposing protocol ambiguity only after site activation.

Real-World Site Impact:

Combination safety requirements increase monitoring intensity and laboratory frequency once sites activate. Tighter visit windows and more complex adverse-event attribution drive additional sponsor queries during active enrollment.

💡

Pro Tip:

During clinical trial protocol development, sites should pressure-test how safety logic functions operationally. Clear, centralized documentation reduces downstream clarification cycles once enrollment begins.

3. (Z)-Endoxifen – Breast Cancer

What It Is:

(Z)-Endoxifen is a Phase 2 study evaluating dosing strategies and comparative outcomes for an oral estrogen receptor modulator in metastatic ER-positive, HER2-negative breast cancer, following encouraging signals from earlier programs.

Why It Matters:

Dose-optimization studies introduce volatility into clinical trial design. Initial dosing assumptions frequently change as exposure and tolerability data accumulates, driving mid-study protocol revisions affecting eligibility thresholds, visit schedules, and monitoring intensity.

Real-World Site Impact:

Sites must re-verify eligibility, update visit calendars, and retrain coordinators as dosing cohorts evolve. Without clear documentation, these changes slow enrollment and increase protocol deviation risk.

💡

Pro Tip:

Strong version control and clinical trial documentation automation help sites understand what changed, why it changed, and how execution is affected, without repeated retraining.

4. α-Lactalbumin Preventive Vaccine – Breast Cancer

What It Is:

This preventive vaccine completed Phase 1 with favorable safety and immune response data and is preparing for Phase 2 evaluation to assess efficacy in high-risk populations without active disease.

Why It Matters:

Preventive trials fundamentally shift clinical trial design priorities from short-term response to long-term safety, immune durability, and sustained participant engagement, extending timelines and altering site operational assumptions.

Real-World Site Impact:

Because preventive vaccine trials require long-term follow-up in otherwise healthy participants, early clinical trial design decisions around visit frequency, safety monitoring, and retention strategy create sustained operational and documentation demands. Sites must plan for extended engagement timelines and ensure continuity in clinical trial documentation over multi-year follow-up periods.

💡

Pro Tip:

During clinical trial protocol development, teams should assess whether long-term follow-up schedules, safety reporting requirements, and participant communication plans are realistic at scale. Early planning for longitudinal clinical trial documentation helps prevent gaps as staff, systems, or participants change over time.

5. NMRA-511 – Alzheimer's Disease

What It Is:

NMRA-511 is an investigational CNS therapy being studied in early clinical development for behavioral symptoms associated with Alzheimer's disease. Initial studies have focused on safety, tolerability, and exploratory behavioral outcome measures to inform dose selection and future clinical trial protocol development.

Why It Matters:

Programs targeting behavioral endpoints introduce variability that directly affects clinical trial design, particularly in how assessments are standardized and documented across sites. Early work in this area often shapes later protocol development decisions around evaluator training, assessment timing, and data consistency requirements.

Real-World Site Impact:

Sites experience higher screen-fail rates when behavioral or cognitive assessments vary across coordinators. Additional time is spent reconciling discrepancies with sponsors, slowing enrollment, and increasing operational burden during screening and early execution.

💡

Pro Tip:

Standardizing evaluator training and assessment documentation before screening begins helps reduce variability. Clear guidance during protocol development improves screening efficiency, strengthens data consistency, and lowers the need for downstream clarification during enrollment.

6. ML-007C-MA – Alzheimer's Psychosis

What It Is:

ML-007C-MA is an investigational therapy in mid-stage clinical evaluation for Alzheimer's disease psychosis. Early clinical studies have focused on safety and dose exploration, with ongoing development helping define appropriate endpoints, eligibility criteria, and study procedures for future clinical protocols.

Why It Matters:

Programs advancing under expedited regulatory pathways often move quickly from early safety studies into larger trials. This compresses timelines for clinical trial protocol development, making early decisions about assessments, visit cadence, and eligibility particularly important for sustainable clinical trial design.

Real-World Site Impact:

When development programs advance quickly under expedited regulatory pathways, there is less room to adjust design assumptions after site activation. This places greater pressure on sites to execute complex eligibility criteria, assessment schedules, and safety monitoring exactly as outlined in the clinical protocols, increasing sensitivity to any ambiguity in early clinical trial design decisions. Sites must complete readiness activities earlier than usual, including staffing, training, and workflow alignment. Delays that might be recoverable in standard timelines directly impact enrollment.

💡

Pro Tip:

During clinical trial protocol development, sites should conduct early feasibility and readiness reviews. Identifying staffing gaps, training needs, and workflow constraints before activation helps mitigate execution risk once compressed Fast Track timelines are in motion.

7. DNL628 / DNL921 – Alzheimer's Disease

What It Is:

DNL628 and DNL921 are investigational biologics designed to address neurodegenerative disease mechanisms using novel delivery approaches intended to improve central nervous system exposure. Early studies are evaluating safety, pharmacokinetics, and target engagement to inform future protocol design.

Why It Matters:

Novel delivery strategies introduce additional considerations for clinical trial design, including dosing verification, safety monitoring, and documentation of administration procedures. These factors increase the need for precise clinical trial documentation and clear alignment between protocol intent and site execution.

Real-World Site Impact:

Sites face higher documentation expectations from the first patient, including detailed source traceability and delivery verification. Coordinators and data teams spend more time reconciling protocol intent with execution reality, increasing administrative workload during early enrollment.

💡

Pro Tip:

Sites benefit from documentation workflows that emphasize traceability from Day 1. Some teams rely on structured environments like Kitsa to maintain alignment across protocol updates while preserving clinical trial documentation integrity as delivery assumptions evolve.

8. Buntanetap (ANVS401) – Parkinson's Disease

What It Is:

Buntanetap (ANVS401) is being evaluated in extended clinical studies focused primarily on long-term safety, tolerability, and exploratory biomarker trends in neurodegenerative disease. These studies provide longitudinal data to inform future development planning and clinical trial protocol development.

Why It Matters:

Long-duration studies test whether clinical trial design is operationally durable. Protocols that function well in early phases often strain over extended timelines, making early decisions around visit cadence, assessments, and staffing continuity critical to long-term execution success.

Real-World Site Impact:

Over time, sites encounter participant fatigue, coordinator turnover, and protocol drift. These cumulative pressures increase deviation risk and erode data consistency, especially when long-term execution assumptions were not stress-tested during protocol development.

💡

Pro Tip:

During clinical trial protocol development, teams should evaluate the long-term feasibility of visit schedules, assessment intensity, and staffing assumptions. Designing durable clinical protocols and scalable clinical trial documentation processes early helps maintain execution quality throughout multi-year studies.

9. GT-02287 – Parkinson's Disease

What It Is:

GT-02287 is an investigational therapy studied in early-phase trials with exploratory biomarker endpoints intended to guide patient selection and future development strategy. Early findings are being used to refine eligibility logic and inform next-stage protocol development.

Why It Matters:

Biomarker-driven programs narrow eligibility windows, tightening constraints within clinical trial design. Screening precision becomes critical, as delays in biomarker confirmation or unclear thresholds directly affect enrollment timelines and overall study feasibility.

Real-World Site Impact:

Sites experience enrollment bottlenecks when laboratory turnaround times or biomarker result availability lag behind protocol expectations. Coordinators may repeatedly re-confirm eligibility, slowing patient progression and increasing screening workload during early enrollment.

💡

Pro Tip:

Clearly documented biomarker thresholds and decision timing during clinical trial protocol development help coordinators screen decisively. Reducing ambiguity around eligibility criteria minimizes rework and improves enrollment efficiency in biomarker-led trials.

10. ART-101 (PSMA Radioligand) – Prostate Cancer

What It Is:

ART-101 is an investigational PSMA-targeted radioligand therapy undergoing early clinical evaluation in prostate cancer. First-in-human studies are designed to assess safety, biodistribution, and imaging characteristics to inform future clinical trial protocol development.

Why It Matters:

Radioligand therapies expand traditional clinical trial design by incorporating nuclear medicine workflows, imaging coordination, and radiation safety procedures. These operational requirements influence site selection, startup timelines, and increase the need for precise clinical trial documentation early in development.

Real-World Site Impact:

Sites encounter startup delays driven by imaging availability, radiation approvals, and coordination between oncology and nuclear medicine teams. Even with strong patient interest, activation timelines slow when imaging workflows and safety processes are not fully aligned during protocol implementation.

💡

Pro Tip:

During clinical trial protocol development, sites should map imaging workflows and departmental responsibilities in detail. Early operational alignment helps prevent activation delays unrelated to recruitment readiness and reduces last-minute adjustments once first-patient dosing is imminent.

11. REC-4881 (MEK1/2 Inhibitor) – Colon Cancer / Hereditary Polyposis

What It Is:

REC-4881 is a Phase 1b/2 study evaluating a MEK1/2 inhibitor in patients with familial adenomatous polyposis. Early data demonstrated rapid and durable reductions in polyp burden, prompting FDA engagement discussions around potential registrational pathways.

Why It Matters:

Rare-disease oncology trials reshape clinical trial design early by prioritizing surrogate endpoints, smaller cohorts, and accelerated regulatory dialogue. These studies demand precise endpoint definition and tightly controlled clinical protocols from the outset.

Real-World Site Impact:

Sites must manage heightened documentation rigor, frequent sponsor interactions, and evolving endpoint interpretation. Even minor ambiguities in clinical trial documentation can trigger clarification cycles that delay execution in small patient populations.

💡

Pro Tip:

During clinical trial protocol development, sites benefit from structured documentation workflows that track endpoint rationale and regulatory assumptions. This reduces rework as registrational discussions evolve and expectations sharpen.

Key Takeaway

Early-phase trials reveal signals that often influence how later clinical trial design and execution unfold, from eligibility criteria and biomarker strategies to visit schedules and documentation demands. Waiting for later phases means reacting to challenges rather than anticipating them.

Kitsa's Trial Watch transforms fragmented early trial activity into structured intelligence, giving clinical development and operations teams earlier visibility into emerging design and feasibility pressures. With this foresight, you can make more informed clinical trial design decisions, anticipate operational demands, and reduce avoidable risks before they materialize across larger programs.

TL;DR

›Early-phase trials surface signals that often shape later clinical trial design
›Eligibility, biomarker strategy, and visit intensity begin to take form earlier than many teams anticipate
›Clinical trial documentation and operational requirements expand as early programs evolve

Act Early to Reduce Clinical Trial Design Risk

Protocol assumptions frequently evolve as data matures, sometimes contributing to downstream amendments.

AI-driven analysis can help teams identify emerging protocol risks earlier in development.

Explore the Early-Phase Trials →

FAQs

Why focus on early-phase trials instead of later-phase studies?+

Because most clinical trial design constraints, eligibility, endpoints, and visit intensity are already locked in by Phase 2. Later phases reveal consequences, not causes.

How does early-phase intelligence reduce amendment risk?+

It highlights where protocol development assumptions may still be evolving, such as eligibility logic, biomarker requirements, or visit schedules, allowing sponsors and study teams to address potential issues before protocols expand across more sites and patients.

Where do sites and study teams struggle most operationally?+

Often, at the intersection of eligibility interpretation, biomarker logistics, and clinical trial documentation, especially when early protocol assumptions evolve and require clarification through formal amendments and updated guidance.

What You Gain:

›Clear visibility into future protocol burden
›Reduced amendment risk through smarter clinical trial protocol development
›Stronger site readiness and feasibility planning
›Faster paths from protocol to patient

Turn early-phase trial signals into smarter clinical trial design decisions with Kitsa.

Reduce Design Risk with Kitsa's Insights Today!

For clinical development and operations leaders, these trials provide early signals that influence feasibility, startup planning, and long-term execution strategy:

Will this mechanism require biomarker-defined enrollment?
Will visit intensity or specialty procedures limit site scalability?
Are protocol assumptions likely to evolve, which may contribute to downstream amendments as development progresses?

Recognizing these signals early allows teams to address design vulnerabilities before they scale into costly protocol amendments or operational delays.

In this article, we aim to facilitate decision intelligence rather than a simple recap. Read on to see which early-phase trials are signaling the biggest shifts in clinical trial design.